{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:53:13Z","timestamp":1780080793995,"version":"3.54.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11102-012-0397-5","type":"journal-article","created":{"date-parts":[[2012,6,6]],"date-time":"2012-06-06T10:59:04Z","timestamp":1338980344000},"page":"330-341","source":"Crossref","is-referenced-by-count":76,"title":["Medical management of Cushing\u2019s disease: what is the future?"],"prefix":"10.1007","volume":"15","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Petersenn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,6,7]]},"reference":[{"issue":"7","key":"397_CR1","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BMK Biller","year":"2008","unstructured":"Biller BMK et al (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"397_CR2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrendo.2011.12","volume":"7","author":"NA Tritos","year":"2011","unstructured":"Tritos NA, Biller BMK, Swearingen B (2011) Management of Cushing disease. Nature Rev Endocrinol 7(5):279\u2013289","journal-title":"Nature Rev Endocrinol"},{"issue":"2","key":"397_CR3","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1210\/jc.2007-2013","volume":"93","author":"CG Patil","year":"2008","unstructured":"Patil CG et al (2008) Late recurrences of Cushing\u2019s disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93(2):358\u2013362","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"397_CR4","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","volume":"96","author":"RN Clayton","year":"2011","unstructured":"Clayton RN et al (2011) Mortality and morbidity in Cushing\u2019s disease over 50\u00a0years in Stoke-on-Trent, UK: audit and meta-analysis of literature. J Clin Endocrinol Metab 96(3):632\u2013642","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"397_CR5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/MED.0b013e328248b498","volume":"14","author":"M Fleseriu","year":"2007","unstructured":"Fleseriu M, Loriaux DL, Ludlam WH (2007) Second-line treatment for Cushing\u2019s disease when initial pituitary surgery is unsuccessful. Curr Opin Endocrinol Diabetes Obes 14(4):323\u2013328","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"397_CR6","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3171\/jns.1989.71.4.0520","volume":"71","author":"RB Friedman","year":"1989","unstructured":"Friedman RB et al (1989) Repeat transsphenoidal surgery for Cushing\u2019s disease. J Neurosurgery 71(4):520\u2013527","journal-title":"J Neurosurgery"},{"issue":"2","key":"397_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022308429992","volume":"5","author":"LK Nieman","year":"2007","unstructured":"Nieman LK (2007) Medical therapy of Cushing\u2019s disease. Pituitary 5(2):77\u201382","journal-title":"Pituitary"},{"issue":"6","key":"397_CR8","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1067\/msy.2002.128482","volume":"132","author":"MT Hawn","year":"2002","unstructured":"Hawn MT et al (2002) Quality of life after laparoscopic bilateral adrenalectomy for Cushing\u2019s disease. Surgery 132(6):1064\u20131069","journal-title":"Surgery"},{"issue":"1","key":"397_CR9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1210\/jc.2006-1328","volume":"92","author":"G Assie","year":"2007","unstructured":"Assie G et al (2007) Corticotroph tumor progression after adrenalectomy in Cushing\u2019s disease: a reappraisal of Nelson\u2019s Syndrome. J Clin Endocrinol Metab 92(1):172\u2013179","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR10","first-page":"167","volume-title":"Endocrine updates vol. 31: Cushing\u2019s disease","author":"S Petersenn","year":"2011","unstructured":"Petersenn S (2011) Medical management of Cushing\u2019s disease. In: Swearingen B, Biller BMK (eds) Endocrine updates vol. 31: Cushing\u2019s disease. Springer, New York, pp 167\u2013182"},{"issue":"19","key":"397_CR11","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","volume":"362","author":"RA Feelders","year":"2010","unstructured":"Feelders RA et al (2010) Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease. N Engl J Med 362(19):1846\u20131848","journal-title":"N Engl J Med"},{"issue":"9","key":"397_CR12","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"96","author":"P Kamenicky","year":"2011","unstructured":"Kamenicky P et al (2011) Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s syndrome. J Clin Endocrinol Metab 96(9):2796\u20132804","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"397_CR13","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-0031-1286297","volume":"43","author":"T Deutschbein","year":"2011","unstructured":"Deutschbein T et al (2011) Measurement of urinary free cortisol by current immunoassays: need for sex-dependent reference ranges to define hypercortisolism. Horm Metab Res 43(10):714\u2013719","journal-title":"Horm Metab Res"},{"issue":"4","key":"397_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1530\/EJE-11-0945","volume":"166","author":"T Deutschbein","year":"2012","unstructured":"Deutschbein T et al (2012) Salivary cortisol as a diagnostic tool for Cushing\u2019s syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. Eur J Endocrinol 166(4):613\u2013618","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"397_CR15","doi-asserted-by":"crossref","first-page":"4482","DOI":"10.1210\/jc.2006-1245","volume":"91","author":"DL Batista","year":"2006","unstructured":"Batista DL et al (2006) The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. J Clin Endocrinol Metab 91(11):4482\u20134488","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"397_CR16","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1210\/jc.79.3.724","volume":"79","author":"Y Greenman","year":"1994","unstructured":"Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79(3):724\u2013729","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"397_CR17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1210\/jc.78.2.398","volume":"178","author":"Y Greenman","year":"1994","unstructured":"Greenman Y, Melmed S (1994) Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 178(2):398\u2013403","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"397_CR18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","volume":"152","author":"LJ Hofland","year":"2005","unstructured":"Hofland LJ et al (2005) The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152(4):645\u2013654","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"397_CR19","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1210\/jc.80.4.1386","volume":"80","author":"GM Miller","year":"1995","unstructured":"Miller GM et al (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80(4):1386\u20131392","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"397_CR20","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1210\/jc.83.8.2997","volume":"83","author":"S Nielsen","year":"1998","unstructured":"Nielsen S et al (1998) Gene transcription of receptors for growth hormone-releasing peptide and somatostatin in human pituitary adenomas. J Clin Endocrinol Metab 83(8):2997\u20133000","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"397_CR21","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0024-3205(94)00956-2","volume":"56","author":"R Panetta","year":"1995","unstructured":"Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56(5):333\u2013342","journal-title":"Life Sci"},{"issue":"6","key":"397_CR22","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000059430","volume":"75","author":"MZ Strowski","year":"2002","unstructured":"Strowski MZ et al (2002) Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinol 75(6):339\u2013346","journal-title":"Neuroendocrinol"},{"issue":"2","key":"397_CR23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/eje.0.1300125","volume":"130","author":"GK Stalla","year":"1994","unstructured":"Stalla GK et al (1994) Octreotide exerts different effects in vivo and in vitro in Cushing\u2019s disease. Eur J Endocrinol 130(2):125\u2013131","journal-title":"Eur J Endocrinol"},{"issue":"1\u20132","key":"397_CR24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0303-7207(99)00161-6","volume":"157","author":"S Petersenn","year":"1999","unstructured":"Petersenn S et al (1999) Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol 157(1\u20132):75\u201385","journal-title":"Mol Cell Endocrinol"},{"issue":"3","key":"397_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF03349555","volume":"13","author":"B Ambrosi","year":"1990","unstructured":"Ambrosi B et al (1990) Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. J Endocrinol Invest 13(3):257\u2013261","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"397_CR26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000125200","volume":"50","author":"SW Lamberts","year":"1989","unstructured":"Lamberts SW et al (1989) Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinol 50(1):44\u201350","journal-title":"Neuroendocrinol"},{"issue":"3","key":"397_CR27","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2265.1990.tb00867.x","volume":"32","author":"C Invitti","year":"1990","unstructured":"Invitti C et al (1990) Treatment of Cushing\u2019s syndrome with the long-acting somatostatin analogue SMS 201\u2013995 (sandostatin). Clin Endocrinol (Oxf) 32(3):275\u2013281","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"397_CR28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0002-9343(93)90283-U","volume":"95","author":"NJ Woodhouse","year":"1993","unstructured":"Woodhouse NJ et al (1993) Acute and long-term effects of octreotide in patients with ACTH-dependent Cushing\u2019s syndrome. Am J Med 95(3):305\u2013308","journal-title":"Am J Med"},{"issue":"5","key":"397_CR29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C et al (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707\u2013716","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"397_CR30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinol 80(Suppl 1):47\u201350","journal-title":"Neuroendocrinol"},{"issue":"2","key":"397_CR31","doi-asserted-by":"crossref","first-page":"E278","DOI":"10.1152\/ajpendo.00004.2005","volume":"289","author":"J Hoek van der","year":"2005","unstructured":"van der Hoek J et al (2005) Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab 289(2):E278\u2013E287","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"397_CR32","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1530\/eje.1.01914","volume":"152","author":"AP Silva","year":"2005","unstructured":"Silva AP et al (2005) Regulation of ghrelin secretion by somatostatin analogs in rats. Eur J Endocrinol 152(6):887\u2013894","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"397_CR33","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1210\/jc.2009-1311","volume":"94","author":"A Ben-Shlomo","year":"2009","unstructured":"Ben-Shlomo A et al (2009) Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab 94(11):4342\u20134350","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"397_CR34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1210\/jc.2008-1008","volume":"94","author":"M Boscaro","year":"2009","unstructured":"Boscaro M et al (2009) Treatment of pituitary-dependent Cushing\u2019s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 94(1):115\u2013122","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"397_CR35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A et al (2012) A 12-month phase 3 study of pasireotide in Cushing\u2019s disease. N Engl J Med 366(10):914\u2013924","journal-title":"N Engl J Med"},{"key":"397_CR36","volume-title":"Summary of product characteristics","author":"Signifor\u00ae","year":"2012","unstructured":"Signifor\u00ae (2012) Summary of product characteristics. Novartis, Basel"},{"issue":"2","key":"397_CR37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2265.2008.03486.x","volume":"71","author":"K Cukier","year":"2009","unstructured":"Cukier K et al (2009) Significant response to pasireotide (SOM230) in the treatment of a patient with persistent, refractory Cushing\u2019s disease. Clin Endocrinol (Oxf) 71(2):305\u2013307","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"397_CR38","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1055\/s-0030-1253419","volume":"118","author":"H Bode","year":"2010","unstructured":"Bode H et al (2010) SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes 118(10):760\u2013763","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"397_CR39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1385\/ENDO:14:3:329","volume":"14","author":"L Stefaneanu","year":"2001","unstructured":"Stefaneanu L et al (2001) Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 14(3):329\u2013336","journal-title":"Endocrine"},{"issue":"5","key":"397_CR40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2265.1981.tb00691.x","volume":"15","author":"EF Adams","year":"1981","unstructured":"Adams EF et al (1981) Bromocriptine suppresses ACTH secretion from human pituitary tumour cells in culture by a dopaminergic mechanism. Clin Endocrinol (Oxf) 15(5):479\u2013484","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1\u20132","key":"397_CR41","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-5793(94)80387-0","volume":"339","author":"D Yin","year":"1994","unstructured":"Yin D et al (1994) Induction of apoptosis in murine ACTH-secreting pituitary adenoma cells by bromocriptine. FEBS Lett 339(1\u20132):73\u201375","journal-title":"FEBS Lett"},{"issue":"4","key":"397_CR42","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1210\/edrv-14-4-443","volume":"14","author":"JW Miller","year":"1993","unstructured":"Miller JW, Crapo L (1993) The medical treatment of Cushing\u2019s syndrome. Endocr Rev 14(4):443\u2013458","journal-title":"Endocr Rev"},{"issue":"2","key":"397_CR43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1365-2265.1988.tb03658.x","volume":"28","author":"AC Hale","year":"1988","unstructured":"Hale AC et al (1988) A bromocriptine-responsive corticotroph adenoma secreting alpha-MSH in a patient with Cushing\u2019s disease. Clin Endocrinol (Oxf) 28(2):215\u2013223","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"397_CR44","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2265.1986.tb03621.x","volume":"25","author":"HP Koppeschaar","year":"1986","unstructured":"Koppeschaar HP et al (1986) Response to neurotransmitter modulating drugs in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 25(6):661\u2013667","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"397_CR45","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R et al (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452\u20132462","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"397_CR46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R et al (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223\u2013230","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"397_CR47","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","volume":"163","author":"A Godbout","year":"2010","unstructured":"Godbout A et al (2010) Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease. Eur J Endocrinol 163(5):709\u2013716","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"397_CR48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade R et al (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356(1):29\u201338","journal-title":"N Engl J Med"},{"issue":"1","key":"397_CR49","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini R et al (2007) Valvular heart disease and the use of dopamine agonists for Parkinson\u2019s disease. N Engl J Med 356(1):39\u201346","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"397_CR50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000314312","volume":"92","author":"M Mannelli","year":"2010","unstructured":"Mannelli M et al (2010) Role of the PPAR-gamma system in normal and tumoral pituitary corticotropic cells and adrenal cells. Neuroendocrinol 92(Suppl 1):23\u201327","journal-title":"Neuroendocrinol"},{"issue":"11","key":"397_CR51","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/nm784","volume":"8","author":"AP Heaney","year":"2002","unstructured":"Heaney AP et al (2002) Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 8(11):1281\u20131287","journal-title":"Nat Med"},{"issue":"3","key":"397_CR52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2265.2006.02610.x","volume":"65","author":"MN Emery","year":"2006","unstructured":"Emery MN et al (2006) PPAR-gamma expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-gamma receptor. Clin Endocrinol (Oxf) 65(3):389\u2013395","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"397_CR53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11102-005-1430-8","volume":"7","author":"AP Heaney","year":"2004","unstructured":"Heaney AP (2004) PPAR-gamma in Cushing\u2019s disease. Pituitary 7(4):265\u2013269","journal-title":"Pituitary"},{"issue":"2","key":"397_CR54","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/eje.0.1510173","volume":"151","author":"B Ambrosi","year":"2004","unstructured":"Ambrosi B et al (2004) Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing\u2019s disease. Eur J Endocrinol 151(2):173\u2013178","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"397_CR55","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2265.2006.02452.x","volume":"64","author":"F Pecori Giraldi","year":"2006","unstructured":"Pecori Giraldi F et al (2006) Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 64(2):219\u2013224","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"397_CR56","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/s-2007-970162","volume":"115","author":"M Morcos","year":"2007","unstructured":"Morcos M et al (2007) Long-term treatment of central Cushing\u2019s syndrome with rosiglitazone. Exp Clin Endocrinol Diabetes 115(5):292\u2013297","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"397_CR57","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1210\/jc.2004-1746","volume":"90","author":"D Suri","year":"2005","unstructured":"Suri D, Weiss RE (2005) Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing\u2019s disease. J Clin Endocrinol Metab 90(3):1340\u20131346","journal-title":"J Clin Endocrinol Metab"},{"issue":"14","key":"397_CR58","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archinternmed.2010.207","volume":"170","author":"SE Nissen","year":"2010","unstructured":"Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Int Med 170(14):1191\u20131201","journal-title":"Arch Int Med"},{"issue":"4","key":"397_CR59","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1517\/14728210903413522","volume":"14","author":"DE Schteingart","year":"2009","unstructured":"Schteingart DE (2009) Drugs in the medical treatment of Cushing\u2019s syndrome. Expert Opin Emerg Drugs 14(4):661\u2013671","journal-title":"Expert Opin Emerg Drugs"},{"issue":"16","key":"397_CR60","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ et al (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171\u20131177","journal-title":"N Engl J Med"},{"issue":"12","key":"397_CR61","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.81.12.3879","volume":"81","author":"RC Gaillard","year":"1984","unstructured":"Gaillard RC et al (1984) RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci 81(12):3879\u20133882","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"397_CR62","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/jcem-61-6-1009","volume":"61","author":"RC Gaillard","year":"1985","unstructured":"Gaillard RC et al (1985) RU 486 inhibits peripheral effects of glucocorticoids in humans. J Clin Endocrinol Metab 61(6):1009\u20131011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"397_CR63","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1210\/jcem-63-3-639","volume":"63","author":"X Bertagna","year":"1986","unstructured":"Bertagna X et al (1986) Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing\u2019s syndrome. J Clin Endocrinol Metab 63(3):639\u2013643","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"397_CR64","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","volume":"157","author":"S Johanssen","year":"2007","unstructured":"Johanssen S, Allolio B (2007) Mifepristone (RU 486) in Cushing\u2019s syndrome. Eur J Endocrinol 157(5):561\u2013569","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"397_CR65","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","volume":"160","author":"F Castinetti","year":"2009","unstructured":"Castinetti F et al (2009) Merits and pitfalls of mifepristone in Cushing\u2019s syndrome. Eur J Endocrinol 160(6):1003\u20131010","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"397_CR66","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1210\/jc.86.8.3568","volume":"86","author":"JW Chu","year":"2001","unstructured":"Chu JW et al (2001) Successful long-term treatment of refractory Cushing\u2019s disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab 86(8):3568\u20133573","journal-title":"J Clin Endocrinol Metab"},{"key":"397_CR67","doi-asserted-by":"crossref","unstructured":"Fleseriu M et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab [Epub ahead of print]","DOI":"10.1210\/jc.2011-3350"},{"key":"397_CR68","unstructured":"ClinicalTrials.gov: http:\/\/www.clinicaltrials.gov . NCT00936741"},{"issue":"6","key":"397_CR69","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1463-1326.2009.01185.x","volume":"12","author":"JK Belanoff","year":"2010","unstructured":"Belanoff JK et al (2010) Selective glucocorticoid receptor (type II) antagonist prevents and reverses olanzapine-induced weight gain. Diabetes Obesity Metab 12(6):545\u2013547","journal-title":"Diabetes Obesity Metab"},{"issue":"12","key":"397_CR70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1056\/NEJM195603222541202","volume":"254","author":"GW Thorn","year":"1956","unstructured":"Thorn GW et al (1956) Inhibition of corticosteroid secretion by amphenone in a patient with adrenocortical carcinoma. N Engl J Med 254(12):547\u2013551","journal-title":"N Engl J Med"},{"issue":"6","key":"397_CR71","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1210\/jcem-16-6-705","volume":"16","author":"R Hertz","year":"1956","unstructured":"Hertz R, Pittman JA, Graff MM (1956) Amphenone: toxicity and effects on adrenal and thyroid function in man. J Clin Endocrinol Metab 16(6):705\u2013723","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"397_CR72","first-page":"E8","volume":"23","author":"JK Liu","year":"2007","unstructured":"Liu JK et al (2007) Treatment options for Cushing disease after unsuccessful transsphenoidal surgery. Neurosurg Focus 23(3):E8","journal-title":"Neurosurg Focus"},{"issue":"8","key":"397_CR73","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1210\/jcem-18-8-906","volume":"18","author":"GW Liddle","year":"1958","unstructured":"Liddle GW et al (1958) Alterations of adrenal steroid patterns in man resulting from treatment with a chemical inhibitor of 11 beta-hydroxylation. J Clin Endocrinol Metab 18(8):906\u2013912","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"397_CR74","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/0022-4731(74)90051-X","volume":"5","author":"DB Gower","year":"1974","unstructured":"Gower DB (1974) Modifiers of steroid-hormone metabolism: a review of their chemistry, biochemistry and clinical applications. J Steroid Biochem 5(5):501\u2013523","journal-title":"J Steroid Biochem"},{"issue":"1","key":"397_CR75","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0889-8529(05)70064-5","volume":"28","author":"N Sonino","year":"1999","unstructured":"Sonino N, Boscaro M (1999) Medical therapy for Cushing\u2019s disease. Endocrinol Metab Clin North Am 28(1):211\u2013222","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"2","key":"397_CR76","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2265.1991.tb03517.x","volume":"35","author":"JA Verhelst","year":"1991","unstructured":"Verhelst JA et al (1991) Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing\u2019s syndrome. Clin Endocrinol (Oxf) 35(2):169\u2013178","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6081","key":"397_CR77","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmj.2.6081.215","volume":"2","author":"WJ Jeffcoate","year":"1977","unstructured":"Jeffcoate WJ et al (1977) Metyrapone in long-term management of Cushing\u2019s disease. Br Med J 2(6081):215\u2013217","journal-title":"Br Med J"},{"issue":"3","key":"397_CR78","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-97-3-370","volume":"97","author":"A Pont","year":"1982","unstructured":"Pont A et al (1982) Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med 97(3):370\u2013372","journal-title":"Ann Intern Med"},{"issue":"12","key":"397_CR79","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/archinte.1982.00340250097015","volume":"142","author":"A Pont","year":"1982","unstructured":"Pont A et al (1982) Ketoconazole blocks testosterone synthesis. Arch Intern Med 142(12):2137\u20132140","journal-title":"Arch Intern Med"},{"issue":"4","key":"397_CR80","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1210\/edrv-7-4-409","volume":"7","author":"D Feldman","year":"1986","unstructured":"Feldman D (1986) Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 7(4):409\u2013420","journal-title":"Endocr Rev"},{"issue":"13","key":"397_CR81","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM198709243171307","volume":"317","author":"N Sonino","year":"1987","unstructured":"Sonino N (1987) The use of ketoconazole as an inhibitor of steroid production. N Engl J Med 317(13):812\u2013818","journal-title":"N Engl J Med"},{"issue":"1","key":"397_CR82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1530\/EJE-07-0514","volume":"158","author":"F Castinetti","year":"2008","unstructured":"Castinetti F et al (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing\u2019s disease. Eur J Endocrinol 158(1):91\u201399","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"397_CR83","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2265.1991.tb03547.x","volume":"35","author":"N Sonino","year":"1991","unstructured":"Sonino N et al (1991) Ketoconazole treatment in Cushing\u2019s syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 35(4):347\u2013352","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"397_CR84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0022-2275(20)38566-7","volume":"29","author":"TA Miettinen","year":"1988","unstructured":"Miettinen TA (1988) Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 29(1):43\u201351","journal-title":"J Lipid Res"},{"issue":"3","key":"397_CR85","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1210\/jcem-63-3-766","volume":"63","author":"AR Glass","year":"1986","unstructured":"Glass AR, Eil C (1986) Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 63(3):766\u2013769","journal-title":"J Clin Endocrinol Metab"},{"issue":"6569","key":"397_CR86","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.294.6569.419","volume":"294","author":"G Lake-Bakaar","year":"1987","unstructured":"Lake-Bakaar G, Scheuer PJ, Sherlock S (1987) Hepatic reactions associated with ketoconazole in the United Kingdom. Br Med J (Clin Res Ed) 294(6569):419\u2013422","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"3","key":"397_CR87","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0016-5085(84)80021-9","volume":"86","author":"JH Lewis","year":"1984","unstructured":"Lewis JH et al (1984) Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86(3):503\u2013513","journal-title":"Gastroenterology"},{"issue":"4","key":"397_CR88","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/eje.1.02120","volume":"154","author":"M Riedl","year":"2006","unstructured":"Riedl M et al (2006) Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 154(4):519\u2013524","journal-title":"Eur J Endocrinol"},{"key":"397_CR89","first-page":"127","volume":"29","author":"N Kaminsky","year":"1962","unstructured":"Kaminsky N, Luse S, Hartroft P (1962) Ultrastructure of adrenal cortex of the dog during treatment with DDD. J Natl Cancer Inst 29:127\u2013159","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"397_CR90","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM197903013000903","volume":"300","author":"JP Luton","year":"1979","unstructured":"Luton JP et al (1979) Treatment of Cushing\u2019s disease by O,p\u2019DDD. Survey of 62 cases. N Engl J Med 300(9):459\u2013464","journal-title":"N Engl J Med"},{"issue":"5","key":"397_CR91","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-92-5-613","volume":"92","author":"DE Schteingart","year":"1980","unstructured":"Schteingart DE et al (1980) Sustained remission of Cushing\u2019s disease with mitotane and pituitary irradiation. Ann Intern Med 92(5):613\u2013619","journal-title":"Ann Intern Med"},{"issue":"1","key":"397_CR92","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2265.1989.tb00453.x","volume":"31","author":"RV Hague","year":"1989","unstructured":"Hague RV, May W, Cullen DR (1989) Hepatic microsomal enzyme induction and adrenal crisis due to o,p\u2019DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf) 31(1):51\u201357","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"397_CR93","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1365-2265.1987.tb01171.x","volume":"27","author":"BG Robinson","year":"1987","unstructured":"Robinson BG et al (1987) The effect of o,p\u2032-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol (Oxf) 27(4):437\u2013444","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"397_CR94","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","volume":"70","author":"HM Schulte","year":"1990","unstructured":"Schulte HM et al (1990) Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing\u2019s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 70(5):1426\u20131430","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"397_CR95","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000088587","volume":"64","author":"JE Greening","year":"2005","unstructured":"Greening JE et al (2005) Efficient short-term control of hypercortisolaemia by low-dose etomidate in severe paediatric Cushing\u2019s disease. Horm Res 64(3):140\u2013143","journal-title":"Horm Res"},{"issue":"2","key":"397_CR96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11102-011-0314-3","volume":"15","author":"J Heyn","year":"2011","unstructured":"Heyn J et al (2011) Medical suppression of hypercortisolemia in Cushing\u2019s syndrome with particular consideration of etomidate. Pituitary 15(2):117\u2013125","journal-title":"Pituitary"},{"issue":"18","key":"397_CR97","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","volume":"124","author":"DA Calhoun","year":"2011","unstructured":"Calhoun DA et al (2011) Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial. Circulation 124(18):1945\u20131955","journal-title":"Circulation"},{"key":"397_CR98","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","volume":"56","author":"L Amar","year":"2010","unstructured":"Amar L et al (2010) Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 56:831\u2013838","journal-title":"Hypertension"},{"key":"397_CR99","unstructured":"Bertagna X et al (2012) Patients with Cushing\u2019s disease achieve normal urinary cortisol with LCI699, a potent 11\u03b2-hydroxylase inhibitor: preliminary results from a multicenter, proof-of-concept study. Endocrine Abstracts 29 OC1.2. Presented at ICE\/ECE 2012, May 5-9, 2012, Florence, Italy"},{"issue":"2","key":"397_CR100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar L et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease. Pituitary 13(2):123\u2013129","journal-title":"Pituitary"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11102-012-0397-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T19:00:02Z","timestamp":1642359602000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-012-0397-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,7]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s11102-012-0397-5","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,7]]}}}